# DESTINY-CRC02 (NCT04744831)

> Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04744831
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Daiichi Sankyo
- Conditions: Advanced Colorectal Cancer
- Interventions: DS-8201a 5.4 mg/kg Q3W; DS-8201a 6.4 mg/kg Q3W
- Enrollment: 122
- Primary outcome: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer

## Commentary we found

- X threads: 31
- YouTube: 30
- Podcasts: 29

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-crc02-nct04744831

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04744831", "email": "<work email>"}; the inbox owner confirms by the emailed link.